|Articles|March 1, 2002
- Applied Clinical Trials-03-01-2002
Selecting Sites and Investigators
The system is an important part of the selection equation in CEE nations where sponsors must contract with institutions rather than investigators. Examples from Hungary offer guidelines for improving selection SOPs.
Advertisement
Articles in this issue
over 24 years ago
Consider Geography When Choosing Investigative Sitesover 24 years ago
Meet the Editorial Advisory Board Francis Crawleyover 24 years ago
9th ACT European Summitover 24 years ago
Letters to the Editorover 24 years ago
Safety and Risk Assessment Gain Importanceover 24 years ago
Transporting Clinical Trial Samplesover 24 years ago
Forward to 2004 or Back to 1984?Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
3
Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5